DIABETIC NEPHROPATHY: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors

    loading  Checking for direct PDF access through Ovid

Abstract

New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.

Related Topics

    loading  Loading Related Articles